|
Partners in Central Nervous System
PROGRESS IN MENTAL HEALTH IS ONE OF THE MAJOR COMMITMENTS OF THE SOLVAY PHARMACEUTICALS COMPANIES.
faverin®/luvox® IS AN IMPORTANT PRODUCT IN PSYCHIATRY WORLDWIDE.
THE LARGEST R & D INVESTMENT IS MADE IN THIS AREA, RESULTING IN THE DISCOVERY AND DEVELOPMENT OF INNOVATIVE COMPOUNDS IN THE AREAS
OF DEPRESSION, ANXIETY AND PSYCHOSIS.
Mental health is an area where diagnosis and treatment is particularly challenging. We are currently witnessing a rapid scientific
evolution in the way psychiatric disorders and the role of biological psychiatry in their treatments are regarded. In this environment,
Solvay feels that for a pharmaceutical company it is not enough to supply innovative, effective and safe medication. Therefore,
Solvay has dedicated to providing total healthcare service to physicians and patients, in the form of collaboration in research,
information and education.
|
|
|
Solvay Pharmaceuticals has housed one of the world's major centres of serotonergic research for more than
20 years. This fundamental research has contributed substantially to the currently available body of knowledge on the involvement of
serotonin in a wide variety of psychiatric disorders such as depression, anxiety, obsessive compulsive disorder and panic.
A tangible result was the discovery of the first SSRI fluvoxamine (faverin®/luvox®).
Its first launch in 1983 represented a break-through in depression treatment. More innovative serotonergic drugs are currently in development for psychosis, depression and anxiety.
|
Solvay Pharmaceuticals betahistine dihydrochloride (Betaserc®),
is the world market leader in the treatment of Ménière's syndrome and vestibular vertigo, and Solvay Pharmaceuticals is a major source of know-how in this field.
In addition to continued betahistine research, Solvay makes considerable contributions to fundamental vertigo research advanced nystagmus investigations are just one example of this fruitful collaboration with the scientific world.
|
